News on research and diagnostic development for pathogenic diseases.
CEO Prahlad Singh said the firm is developing a PCR- and antibody-based assay for the novel coronavirus 2019-nCoV and is working with the Chinese NMPA.
The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.
The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.
The company said it has started the CE mark approval process of commissioned high-risk HPV genotyping assays and expects to certify them this year.
The partners will use Noscendo's Disqver next-generation sequencing-based diagnostic platform to characterize antibiotic-resistant pathogens.
